For years, the conversation around AI in pharmaceuticals has focused on capability: better models, faster insights, more automation, smarter predictions. But that era is ending.
The next phase of AI adoption in pharma is about who owns the intelligence it depends on, who controls how that intelligence is used, and who ultimately captures the value it creates. Agentic AI is accelerating this shift, quietly redefining what “buy vs build” really means for pharmaceutical companies.
Where value actually lives
In pharmaceuticals, the most valuable assets have never been the tools themselves. The value is in:
- Proprietary scientific and clinical data
- Deep domain expertise held by scientists, clinicians, and operators
- Institutional decision logic: how tradeoffs are evaluated, escalated, and approved
- Regulatory reasoning and risk posture
- End to end accountability under regulatory scrutiny
Historically, much of this intelligence lived in people, processes, and documents. Software helped organize and analyze it, but ownership was never in question. That assumption no longer holds as data management shifts further toward technology.
LLMs change the economics of data
LLMs have made this reality impossible to ignore: data is the limiting resource. Models require vast amounts of high quality, domain specific data to improve. The most capable AI systems in the world are trained on enormous datasets, and companies pay extraordinary sums to access differentiated data sources. This is already visible in exclusive data licensing agreements, premium pricing for proprietary corpora, and strategic partnerships built entirely around data access.
Pharmaceutical companies sit on some of the most valuable data in existence. In an AI driven economy, this data becomes leverage. Pharma companies should be thinking about their data the same way frontier AI labs do: as a strategic asset that compounds value when protected.
The quiet tradeoff embedded in modern SaaS
Most enterprise SaaS platforms are learning systems rather than neutral tools. To improve their products, vendors routinely collect usage patterns, metadata about workflows and decisions, aggregated behavioral signals, and performance and outcome telemetry.
This data is often framed as necessary to make the solution better, more accurate, or more efficient. And in many cases, that’s true, but there’s an implicit tradeoff. The same data that improves the customer experience also:
- Trains vendor models
- Informs product roadmaps
- Strengthens proprietary algorithms
- Increases the long term value of the vendor’s platform
In practice, customers are often helping vendors compound intelligence that they no longer own. For many industries, this tradeoff has been acceptable. In pharma, it’s increasingly problematic.
Why agentic AI raises the stakes
Agentic AI systems do more than just process data. They reason across it, learning from outcomes and encoding judgment, escalation patterns, and expert behavior over time. That means the data being generated becomes institutional intelligence.
When that intelligence is captured inside vendor platforms, pharma companies risk externalizing:
- How decisions are made
- How risk is assessed
- How regulatory judgment evolves
- How expertise compounds over time
Once expert reasoning and decision logic are embedded outside the enterprise boundary, they’re difficult to reclaim. Agentic AI makes it possible to own this intelligence internally. It also makes it dangerous not to.
From buying decisions to owning decision systems
Traditional enterprise AI platforms were built for a world where intelligence was centralized, logic was configured rather than composed, and decisions flowed through monolithic systems. That model breaks down in regulated, high stakes environments like pharma. Today’s leading organizations want:
- Control over how agents reason, not just what they output
- Transparency into why decisions were made
- The ability to evolve logic as science and regulation change
- Clear human in the loop authority
They want decision systems they own and control over their proprietary data.
Regulatory reality reinforces this case for ownership. In pharmaceuticals, accountability can’t be outsourced. Regulators expect traceability, rationale, and human oversight. Agentic systems can provide this, but only when enterprises control the architecture, data flows, and reasoning layers. Black box AI platforms that extract intelligence while obscuring logic increasingly represent risk.
The talent shift pharma can't avoid
Owning agentic systems means owning the skills required to design, evaluate, and govern them. That includes:
- Scientists who understand how expertise becomes agent behavior
- Quality and compliance teams fluent in AI driven decision trails
- Digital teams orchestrating agents instead of dashboards
- Leaders who understand AI systems as evolving infrastructure
The most forward looking pharma organizations are already investing in this shift, quietly building internal AI capabilities that look far closer to applied AI labs than traditional IT functions.
Pharma must learn to think like an AI lab
If data and expert knowledge are the keys to the kingdom, agentic AI is the system that governs access, use, and evolution of both. Agentic AI captures how organizations think, not just what they know. It encodes judgment, handles uncertainty, and improves through feedback over time. That makes it a strategic capability.
Adopting agentic AI requires an organizational shift. To succeed in this next phase, pharma companies must begin to think less like software buyers and more like AI labs operating inside regulated enterprises. This means:
- Treating data as capital
- Designing reasoning pathways, not just workflows
- Continuously evaluating outcomes over time
- Governing systems as living assets
Successful AI adoption requires modernizing how intelligence is built and stewarded.
How working with Turing supports this shift
Making this transition responsibly requires exposure to how frontier AI systems are built, evaluated, and governed. Turing works with pharmaceutical companies to help them:
- Build agentic systems they own
- Protect data sovereignty and institutional knowledge
- Apply frontier AI methodologies in regulated environments
- Upskill internal teams to steward these systems long term
Rather than owning customer intelligence, Turing focuses on accelerating internal capability so organizations can move quickly without giving up control.
What this means for pharma leaders
The defining question is no longer: “What can this AI platform do for us?”
It’s: “What intelligence are we giving up, and what could it be worth if we owned it?”
In an era where LLMs thrive on data and agentic systems encode expertise, the most defensible advantage pharmaceutical companies can build is ownership of their intelligence, end to end. And in the next decade of AI driven pharma, it may be the difference between leading and being leveraged.
The next phase of AI will be defined by who can make intelligence work reliably in the real world. Progress now depends on closing the loop between frontier advancement and enterprise deployment, where real constraints generate real signals that feed directly back into better data, systems, and models. This is where capability compounds and where lasting advantage is created.
Turing operates at this intersection. We accelerate frontier AI by advancing the data, systems, and talent that push model capability forward, and we deploy that intelligence inside enterprises. If you’re ready to move beyond experimentation and turn AI into sustainable infrastructure, talk to a Turing Strategist about putting this loop to work in production.
Have the model—but not the right data?
Turing provides human-generated, proprietary datasets and world-class tuning support to get your LLM enterprise-ready.